Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Background/Aims Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of vedolizumab clearance may enhance dose and treatment s...

Full description

Bibliographic Details
Main Authors: Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori, Toshifumi Hibi
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2021-01-01
Series:Intestinal Research
Subjects:
population pharmacokinetics
vedolizumab
colitis, ulcerative
crohn disease
asian
Online Access:http://www.irjournal.org/upload/pdf/ir-2019-09167.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-2019-09167.pdf

Similar Items